These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34646229)

  • 1. Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat
    Fernandez O; Costa-Frossard L; Martínez-Ginés ML; Montero P; Prieto-González JM; Ramió-Torrentà L
    Front Neurol; 2021; 12():722801. PubMed ID: 34646229
    [No Abstract]   [Full Text] [Related]  

  • 2. Spasticity-Plus syndrome in multiple sclerosis patients in a tertiary hospital in Spain.
    Goicochea Briceño H; Higueras Y; Ruiz Pérez I; García Domínguez JM; Cuello JP; Meldaña Rivera A; Martínez Ginés ML
    Front Neurol; 2024; 15():1360032. PubMed ID: 38469589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms.
    Fernández Ó; Costa-Frossard L; Martínez-Ginés M; Montero P; Prieto JM; Ramió L
    Front Neurol; 2020; 11():152. PubMed ID: 32256440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
    Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis.
    Fernández Fernández Ó; Costa-Frossard L; Martínez Ginés ML; Montero Escribano P; Prieto González JM; Ramió-Torrentà L; Aladro Y; Alonso Torres A; Álvarez Rodríguez E; Labiano-Fontcuberta A; Landete Pascual L; Miralles Martínez A; Moral Torres E; Oliva-Nacarino P
    Front Neurol; 2024; 15():1371644. PubMed ID: 38708001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical and Therapeutic Implications of the Spasticity-Plus Syndrome Model in Multiple Sclerosis.
    Bruno A; Dolcetti E; Centonze D
    Front Neurol; 2021; 12():802918. PubMed ID: 35197915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
    Patti F; Chisari CG; Fernández Ó; Sarroca J; Ferrer-Picón E; Hernández Vicente F; Vila Silván C
    Eur J Neurol; 2022 Sep; 29(9):2744-2753. PubMed ID: 35590453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Patti F; Chisari CG; Solaro C; Benedetti MD; Berra E; Bianco A; Bruno Bossio R; Buttari F; Castelli L; Cavalla P; Cerqua R; Costantino G; Gasperini C; Guareschi A; Ippolito D; Lanzillo R; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Russo M; Saccà F; Salamone G; Signoriello E; Spinicci G; Spitaleri D; Tavazzi E; Trotta M; Zaffaroni M; Zappia M;
    Neurol Sci; 2020 Oct; 41(10):2905-2913. PubMed ID: 32335779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing the symptoms of multiple sclerosis: a multimodal approach.
    Crayton HJ; Rossman HS
    Clin Ther; 2006 Apr; 28(4):445-60. PubMed ID: 16750459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    Fernández O
    Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis symptoms and spasticity management: new data.
    Izquierdo G
    Neurodegener Dis Manag; 2017 Nov; 7(6s):7-11. PubMed ID: 29143581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis spasticity: 'state-of-the-art' questionnaire survey of specialized healthcare professionals.
    Collongues N; Vermersch P
    Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):21-5. PubMed ID: 23369056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic therapy of multiple sclerosis.
    Markowitz C
    Continuum (Minneap Minn); 2010 Oct; 16(5 Multiple Sclerosis):90-104. PubMed ID: 22810600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.